Population Shifts, Risk Factors May Triple U.S. Cardiovascular Disease Costs by 2050

This AHA press release announces two companion presidential advisories — one modeling CVD prevalence through 2050, one projecting costs — that together amount to the most comprehensive forward-looking picture of the US cardiovascular burden yet assembled. The underlying work, published in Circulation, projects that more than 61% of US adults (184 million people) will have some form of cardiovascular disease by 2050, up from 128 million today. Total CVD-related costs are projected to triple to $1.8 trillion — nearly doubling CVD’s share of GDP from 2.7% to 4.6%.

The driving forces are well-specified: an aging population (the last baby boomers turn 65 in 2030), rising obesity (projected to increase from 43% to 61% of adults), expanding diabetes prevalence (16% to 27%), and demographic shifts that will push CVD burden disproportionately toward Hispanic and Asian populations. Stroke-related costs alone are projected to increase 535%, from $67 billion to $423 billion. Medicare CVD costs would more than triple. The projections are not uniformly grim — smoking rates are projected to halve, and physical inactivity rates to improve — but these gains are overwhelmed by the trajectory of metabolic risk.

The advisories model two intervention scenarios. Modest improvements — reducing risk factor prevalence by roughly 10% and improving control by 20% — could prevent 1.2 million cardiovascular events and 240,000 deaths annually by 2050. A more aggressive scenario (halving obesity, doubling risk factor control) could prevent more than 2.3 million events and 450,000 deaths per year. These scenarios establish that the trajectory is not fixed.

The underlying methodology is sound: 2020 baseline data from nationally representative sources, cost projections in 2022 dollars using established inflation assumptions, validated demographic trend data from the Census Bureau. The model does not incorporate GLP-1 receptor agonists — an acknowledged limitation that could materially alter the obesity and diabetes trajectories.

We rate the evidence strong. These AHA presidential advisories, modeling CVD prevalence and economic burden through 2050, establish that the US faces a structural cardiovascular crisis driven by aging demographics and rising metabolic disease — and that aggressive prevention could substantially alter that trajectory.